TABLE 5.
Unadjusted and Adjusted Health Care Costs During Baseline and Study Periods a
| Telaprevir Patients (n = 871) | Boceprevir Patients (n = 284) | P Valuec | |
|---|---|---|---|
| Unadjusted Health Care Costs ($) | |||
| Baseline period (6 months) costs, mean ± SD | |||
| Medical costs | 7,107 ± 36,348 | 5,562 ± 9,242 | |
| IP costs | 1,123 ± 12,811 | 972 ± 4,750 | |
| ER costs | 556 ± 12,395 | 161 ± 547 | |
| OP costs | 5,427 ± 25,938 | 4,429 ± 7,251 | |
| Drug costs | 2,834 ± 17,352 | 3,151 ± 5,245 | |
| Drug costs for CHC treatment | 809 ± 2,678 | 1,931 ± 4,145 | |
| Other drug costs | 2,024 ± 16,979 | 1,220 ± 3,340 | |
| Study period (12 months) costs, mean ± SD | |||
| Medical costs | 19,519 ± 57,986 | 16,927 ± 40,915 | |
| IP costs | 7,975 ± 42,729 | 7,607 ± 34,589 | |
| ER costs | 430 ± 1,742 | 462 ± 1,144 | |
| OP costs | 11,114 ± 35,661 | 8,858 ± 12,187 | |
| Drug costs | 76,497 ± 37,341 | 59,953 ± 41,665 | |
| Drug costs for CHC treatment | 69,426 ± 21,210 | 51,014 ± 24,657 | |
| Other drug costs | 7,071 ± 31,287 | 8,939 ± 29,831 | |
| Adjusted Health Care Costsb ($) | |||
| Study period (12 months) costs, mean (SE) | |||
| Medical costs | 18,148 (1,593) | 18,301 (2,181) | 0.966 |
| IP costs | 7,507 (1,363) | 9,476 (2,915) | 0.475 |
| ER costs | 421 (46) | 486 (76) | 0.491 |
| OP costs | 9,848 (721) | 9,663 (769) | 0.881 |
| Drug costs | 76,560 (1,180) | 59,678 (2,254) | < 0.001 |
a The baseline period was defined as 6 months before the index date, and the study period was defined as 12 months after the index date.
b All models included the following covariates: cohort (telaprevir or boceprevir), gender, age, prior CHC treatment, CCI, and the log of baseline cost of the same type. One-part generalized linear regression models with a gamma distribution and log link were used for the comparison of total medical costs, OP costs, and drug costs. Two-part models were used for IP and ER costs, since zero costs were observed in more than 5% of the patients.
c P values were obtained using a bootstrap-based approach (1,000 replications). The Kolmogorov-Smirnov test for the equality of distributions was used to test the null hypothesis that the adjusted costs for telaprevir and boceprevir arise from identical distributions.
CCI = Charlson Comorbidity Index; CHC = chronic hepatitis C; ER = emergency room; IP = inpatient; OP = outpatient; SD = standard deviation; SE = standard error.